American Society of Hirudotherapy

An increase in activity of serotonergic Retzius neurones may not be necessary for the consummatory phase of feeding in the leech Hirudo medicinalis.

Research article published in The Journal of experimental biology (1996)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genomics & ProteomicsSalivary PharmacologyWilson et al. · The Journal of experimental biology, 1996

Abstract

During the consummatory phase of feeding, in which blood is ingested, medicinal leeches display a characteristic set of behaviours: they extend their jaws, are less responsive to sensory input, produce mucus, relax the body wall and exhibit waves of peristalsis that can run the length of the body. Earlier reports suggested that this pattern of behaviour is orchestrated by serotonin released from Retzius cells in response to the appropriate sensory stimulation of the lip. We have developed a semi-intact preparation in which only the nervous system in the posterior half of the leech was exposed. The front half of the leech was free to explore, bite through and feed until satiated from a blood-filled sausage casing while continuous intracellular and extracellular recordings were made from identified cells and the nerve roots of the exposed segments. Prior to attachment of the animal to the feeding device, the firing frequency of the Retzius cell increased transiently during spontaneous movements or tactile stimuli to its front or posterior end. In contrast, Retzius cell activity decreased after the anterior sucker attached to the membrane of the feeding device at about the time when ingestion was initiated. Increased activity of Leydig cells, which are known to modulate several circuits in the leech, was also associated with exploration. However, unlike that of Retzius cells, the activity of Leydig cells increased significantly following the onset of consumption. These results suggest that increased activity of Retzius cells in midbody ganglia is not a prerequisite for the consummatory phase of feeding and raises questions regarding the role of serotonin in regulating this behaviour.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, U.S. Gov't, Non-P.H.S.Research Support, U.S. Gov't, P.H.S.
Indexed MeSH termsAnimalsAppetitive BehaviorConsummatory BehaviorElectrophysiologyFeeding BehaviorGanglia, InvertebrateLeechesLeydig CellsMaleNeuronsSerotonin

Summary

During the consummatory phase of feeding, in which blood is ingested, medicinal leeches display a characteristic set of behaviours: they extend their jaws, are less responsive to sensory input, produce mucus, relax the body wall and exhibit waves of peristalsis that can run the length of the body....

Why This Matters for Hirudotherapy

The abstract describes an electrophysiological preparation in medicinal leeches in which the front half fed from a blood-filled sausage casing while recordings were made from identified neurons and nerve roots in the exposed posterior nervous system. It reports that Retzius cell activity decreased around attachment and ingestion, whereas Leydig cell activity increased after consumption began, challenging the view that increased Retzius/serotonin activity is required for the consummatory feeding phase. The work concerns leech feeding behavior and neuromodulation. The abstract does not mention hirudotherapy, the salivary secretome, or therapeutic applications, so its relevance to ASH's clinical/therapeutic domain is negligible.

Citation

An increase in activity of serotonergic Retzius neurones may not be necessary for the consummatory phase of feeding in the leech Hirudo medicinalis.

Wilson et al. · The Journal of experimental biology, 1996

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.